Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
IN
Inhibrx Biosciences, Inc. Common Stock
INBX
Mkt Cap
$1.32B
Volume
118.04K
Next Earnings
November 13th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
IN
INBX
IN
Inhibrx Biosciences, Inc. Common Stock
INBX
News
·
Chondrosarcoma Clinical Trial Pipeline: Emerging Therapies and Key Developments Shaping the Treatment Landscape | DelveInsight
Mkt Cap
$1.32B
Volume
118.03K
Next Earnings
November 13th
Chart
Financials
Earnings
News
About
Insider
Filings
Chondrosarcoma Clinical Trial Pipeline: Emerging Therapies and Key Developments Shaping the Treatment Landscape | DelveInsight
DelveInsight released a comprehensive report on the chondrosarcoma clinical trial pipeline, highlighting 5+ emerging therapies in development by key players. Notable drugs include Ozekibart (INBRX-109) which received FDA acceptance for filing with a PDUFA goal date of April 2027, Ivosidenib in Phase III trials, and RBT-102 in preclinical stages. The pipeline focuses on novel mechanisms including DR5 agonism and IDH1 inhibition to address this rare, high-unmet-need oncology market.
GlobeNewswire Inc. · Sep 1, 2026
Inhibrx Reports First Quarter 2026 Financial Results
Inhibrx Biosciences reported Q1 2026 results with a net loss of $33.4 million ($2.15 per share), improved from $43.3 million in Q1 2025. The company raised $75 million in debt financing, bringing cash to $161.7 million. R&D expenses decreased to $25.2 million due to lower clinical trial costs. Key programs include INBRX-106 for head and neck cancer with Phase 2 PFS data expected in Q4 2026, and ozekibart (INBRX-109) for colorectal cancer and chondrosarcoma with a BLA submitted to the FDA.
Benzinga · May 14, 2026
Large Drugmakers Eye Inhibrx Cancer Drugs Valued Over $8 Billion, Stock Surges
Inhibrx Biosciences is in early-stage discussions with multiple major pharmaceutical companies regarding a potential joint spin-off of its cancer drug INBRX-106 and another oncology asset, with combined valuations potentially exceeding $9 billion. INBRX-106 is being tested as a standalone therapy and in combination with Merck's Keytruda. The stock surged 39.86% to $116.76 on the news.
Benzinga · Apr 22, 2026
Stocks Soar To Records After Weak Inflation, Ford Jumps 10%: What's Moving Markets Friday?
U.S. stock markets hit record highs after September's inflation data showed a softer-than-expected 3% annual rate, boosting investor confidence in potential Federal Reserve interest rate cuts. Major indices like S&P 500 and Dow Jones reached new peaks, with technology stocks leading the rally.
Benzinga · Oct 24, 2025
Why Are Inhibrx Biosciences Shares Soaring 76% After Hours?
Inhibrx Biosciences announced positive Phase 2 trial results for ozekibart in treating chondrosarcoma, demonstrating significant progression-free survival improvement and becoming the first experimental therapy to show such benefit in this cancer type.
Benzinga · Oct 24, 2025
Inhibrx stock rated 'Market Perform' by JMP after Sanofi acquisition - Investing.com
JMP Securities initiated coverage on Inhibrx Inc. with a Market Perform rating following the acquisition of INBRX-101 by Sanofi. The newly formed Inhibrx Biosciences has a strong financial foundation, but faces challenges with negative profitability metrics.
Investing.com · Jul 23, 2024
Inhibrx, Inc. (INBX) Reports Q4 Loss, Tops Revenue Estimates
Inhibrx, Inc. (INBX) delivered earnings and revenue surprises of -61.68% and 1,534%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Zacks Investment Research · Feb 28, 2024
BioMarin Pharmaceutical (BMRN) Beats Q4 Earnings and Revenue Estimates
BioMarin (BMRN) delivered earnings and revenue surprises of 11.36% and 1.49%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Zacks Investment Research · Feb 22, 2024
Pharma Stock Roundup: JNJ Reports Q4 Earnings, SNY Inks M&A Deal With INBX
J&J (JNJ) beats estimates for fourth-quarter earnings and sales. Sanofi (SNY) is set to acquire Inhibrx's (INBX) rare disease pipeline candidate, INBRX-101.
Zacks Investment Research · Jan 25, 2024
Biotech Stock Roundup: GILD Down on Study Results, INBX Gains on Sanofi Deal & More
Gilead Sciences (GILD) and Inhibrx (INBX) are in the spotlight on regulatory and pipeline updates.
Zacks Investment Research · Jan 24, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
IN
INBX
Inhibrx Biosciences, Inc. Common Stock
Buy
Sell
Market
Limit
Soon
INBX
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any INBX yet.
Related Tickers
Earnings